Exchange: NASDAQ·Updated 04:01 AM EDT
CRVS logo

CRVS Corvus Pharmaceuticals Inc

$10.82
$0.08
(0.73%)
Pre-Market
Prev Close $10.90
EarningsNov 3
Mkt Cap$916.92M
Vol186.00

About CRVS

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.
67

Bullish Sentiment

How do you feel about CRVS?

Advertisement|Remove ads.